Patents by Inventor Hyung-Kyu Lim
Hyung-Kyu Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082355Abstract: Provided are a liquid formulation of protein and a method of preparing the same. According to a liquid formulation containing a high concentrate of eflapegrastim and a method of preparing the same, the liquid formulation may have excellent solubility and stability, may have a high concentration of protein, and may be injected in a patient-friendly manner due to reduced irritation/pain at the administration site or patient discomfort.Type: ApplicationFiled: January 26, 2022Publication date: March 14, 2024Applicant: Hanmi Pharm. Co., Ltd.Inventors: Hyung Kyu LIM, Sang Yun KIM, Sung Hee HONG
-
Publication number: 20230285583Abstract: A liquid formulation of a long-acting conjugate of glucagon, GLP-1, and GIP trigonal agonist, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 920 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 5.0 to 7.0, and 0.5% (w/v) to 10% (w/v) of a sugar alcohol, saccharide, or a combination thereof.Type: ApplicationFiled: May 24, 2021Publication date: September 14, 2023Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu LIM, Sang Yun KIM, Sung Min BAE
-
Publication number: 20230220034Abstract: A method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment is disclosed. The method includes steps of conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment. Also disclosed is a composition for improving the solubility of a physiologically active protein or peptide, which contains an immunoglobulin Fc fragment. The composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.Type: ApplicationFiled: June 13, 2022Publication date: July 13, 2023Applicant: HANMI PHARM. CO., LTDInventors: Hyung Kyu LIM, Jong Soo LEE, Dae Jin KIM, Sung Min BAE, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20230192800Abstract: A liquid formulation of a long-acting conjugate of glucagon, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 936 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.8 to 6.5, and 1.Type: ApplicationFiled: May 24, 2021Publication date: June 22, 2023Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu LIM, Joo Young DONG, Sang Yun KIM, Sung Min BAE
-
Publication number: 20220118103Abstract: A method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof is disclosed. The method includes site-specifically binding a carrier to a protein or peptide. A protein or peptide produced by the method and the uses thereof are disclosed. The conjugate of the physiologically active protein or peptide can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.Type: ApplicationFiled: December 30, 2021Publication date: April 21, 2022Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Hee PARK, Seung Su KIM, Hyung Kyu LIM, Jae Hyuk CHOI, In Young CHOI, Se Chang KWON
-
Patent number: 11071785Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: GrantFiled: March 18, 2019Date of Patent: July 27, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20210138070Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.Type: ApplicationFiled: December 28, 2020Publication date: May 13, 2021Applicant: HANMI PHARM. CO., LTD.Inventors: Hwa Peoung RIM, Hyun Uk KIM, Ho Taek IM, Sang Yun KIM, Hyung Kyu LIM, Sung Min BAE, Se Chang KWON
-
Patent number: 10987424Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.Type: GrantFiled: July 25, 2013Date of Patent: April 27, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Min Young Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 10987425Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.Type: GrantFiled: September 26, 2014Date of Patent: April 27, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Hwa Peoung Rim, Hyun Uk Kim, Ho Taek Im, Sang Yun Kim, Hyung Kyu Lim, Sung Min Bae, Se Chang Kwon
-
Patent number: 10647753Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.Type: GrantFiled: May 25, 2018Date of Patent: May 12, 2020Assignee: HANMI PHARM. CO., LTD.Inventors: Jin Young Kim, Euh Lim Oh, Jong Soo Lee, Hyung Kyu Lim, In Young Choi, Se Chang Kwon
-
Patent number: 10487128Abstract: Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form.Type: GrantFiled: July 14, 2014Date of Patent: November 26, 2019Assignee: HANMI PHARM. CO., LTDInventors: Sung Hee Park, Min Young Kim, Hyung Kyu Lim, Sung Min Bae, Sung Youb Jung, Se Chang Kwon
-
Patent number: 10441665Abstract: Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: GrantFiled: September 25, 2017Date of Patent: October 15, 2019Assignee: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20190269779Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: ApplicationFiled: March 18, 2019Publication date: September 5, 2019Inventors: HYUN UK KIM, HYUNG KYU LIM, MYUNG HYUN JANG, SANG YUN KIM, SUNG MIN BAE, SE CHANG KWON
-
Patent number: 10279041Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: GrantFiled: June 29, 2017Date of Patent: May 7, 2019Assignee: Hanmi Pharm Co. Ltd.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20190022183Abstract: The present invention relates to a liquid formulation of a long-acting human growth hormone conjugate and a preparation method thereof.Type: ApplicationFiled: December 30, 2016Publication date: January 24, 2019Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu LIM, Joo Young DONG, Sung Min BAE, Se Chang KWON
-
Publication number: 20180344866Abstract: A liquid formulation of highly concentrated long-acting human growth hormone conjugate contains a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent. A method for preparing the same is provided.Type: ApplicationFiled: July 25, 2018Publication date: December 6, 2018Applicant: HANMI SCIENCE CO., LTD.Inventors: Hyung Kyu LIM, Hyun Uk KIM, Sung Hee HONG, Sung Min BAE, Se Chang KWON
-
Publication number: 20180282388Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.Type: ApplicationFiled: May 25, 2018Publication date: October 4, 2018Applicant: HANMI PHARM. CO., LTDInventors: Jin Young KIM, Euh Lim OH, Jong Soo LEE, Hyung Kyu LIM, In Young CHOI, Se Chang KWON
-
Patent number: 10064951Abstract: The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same.Type: GrantFiled: March 23, 2013Date of Patent: September 4, 2018Assignee: HANMI SCIENCE CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
-
Patent number: 10017557Abstract: Insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described.Type: GrantFiled: August 29, 2016Date of Patent: July 10, 2018Assignee: HANMI PHARM. CO., LTD.Inventors: Jin Young Kim, Euh Lim Oh, Jong Soo Lee, Hyung Kyu Lim, In Young Choi, Se Chang Kwon
-
Publication number: 20180015175Abstract: Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: ApplicationFiled: September 25, 2017Publication date: January 18, 2018Applicant: HANMI PHARM. CO., LTD.Inventors: Hyun Uk KIM, Hyung Kyu LIM, Sung Hee HONG, Dae Jin KIM, Sung Min BAE, Se Chang KWON